Dutta P, Mitra U, Dutta S, De A, Chatterjee M K, Bhattacharya S K
Divisions of Clinical Medicine & Microbiology, National Institute of Cholera & Enteric Diseases (ICMR), Kolkata, India.
Indian J Med Res. 2001 Jun;113:210-3.
BACKGROUND & OBJECTIVES: The rapid spread of multidrug resistant (MDR) typhoid fever has posed a great challenge for the treatment of these cases the world over. After the emergence of chloramphenicol resistant Salmonella typhi strains, ciprofloxacin has become the drug of choice for the treatment of typhoid fever even in the paediatric age group. This study evaluated the role of ceftriaxone therapy in bacteriologically confirmed MDR typhoid cases who did not respond to 12-14 days of ciprofloxacin therapy. Attempts have also been made to investigate the in vitro susceptibility of isolated S. typhi strains to chloramphenicol, ciprofloxacin and ceftriaxone.
A total of 140 children, aged 3-10 yr, clinically diagnosed as having typhoid fever, without any clinical response after 12-14 days of ciprofloxacin therapy were screened for S. typhi by blood culture. In the bacteriologically positive children the treatment was changed to intravenous ceftriaxone for 14 days. The isolated strains of S. typhi were tested for in vitro antimicrobial susceptibility.
Clinical and bacteriological cure was observed with intravenous ceftriaxone therapy in all the 32 bacteriologically positive patients. All isolated S. typhi strains were uniformly (100%) susceptible to ciprofloxacin and ceftriaxone but 50 per cent of the strains were resistant to chloramphenicol. The MIC values of chloramphenicol, ciprofloxacin and ceftriaxone ranged between 125-500, 0.0625-0.5 and < 0.0625 microgram/ml respectively.
INTERPRETATION & CONCLUSION: The study indicates that although the S. typhi strains were susceptible to ciprofloxacin in vitro, the patients did not respond clinically and bacteriologically to ciprofloxacin therapy. Hence, ciprofloxacin may not represent a reliable and useful option for treating MDR typhoid fever; ceftriaxone may be an effective alternative for the treatment of such cases.
多重耐药伤寒热的迅速传播给全球此类病例的治疗带来了巨大挑战。在耐氯霉素伤寒沙门氏菌菌株出现后,环丙沙星已成为治疗伤寒热的首选药物,甚至在儿童年龄组也是如此。本研究评估了头孢曲松治疗对环丙沙星治疗12 - 14天无反应的细菌学确诊多重耐药伤寒病例的作用。还尝试研究分离出的伤寒沙门氏菌菌株对氯霉素、环丙沙星和头孢曲松的体外敏感性。
总共140名3 - 10岁临床诊断为伤寒热的儿童,在环丙沙星治疗12 - 14天后无任何临床反应,通过血培养筛查伤寒沙门氏菌。在细菌学阳性的儿童中,治疗改为静脉注射头孢曲松14天。对分离出的伤寒沙门氏菌菌株进行体外抗菌敏感性测试。
在所有32例细菌学阳性患者中,静脉注射头孢曲松治疗观察到临床和细菌学治愈。所有分离出的伤寒沙门氏菌菌株对环丙沙星和头孢曲松均呈一致(10000%)敏感,但50%的菌株对氯霉素耐药。氯霉素、环丙沙星和头孢曲松的最低抑菌浓度值分别在125 - 500、0.0625 - 0.5和<0.0625微克/毫升之间。
该研究表明,尽管伤寒沙门氏菌菌株在体外对环丙沙星敏感,但患者对环丙沙星治疗在临床和细菌学上均无反应。因此,环丙沙星可能不是治疗多重耐药伤寒热的可靠和有用选择;头孢曲松可能是治疗此类病例的有效替代药物。